Caplin Point Laboratories Valuation Multiples

Caplin Point Laboratories Overview

About Caplin Point Laboratories

Caplin Point Laboratories Ltd is an India-based pharmaceutical company. It is engaged in the manufacturing and marketing of pharmaceutical products. The company's key products include tablets, capsules, injections (liquid and lyophilized, prefilled syringes), ophthalmic solutions, liquid orals, soft gel capsules, ointments, creams, gels, powders for injections, suppositories, ovules, pre-mix bag formulations, inhalers, sprays, and IV infusions. It also provides pharmaceutical formulations in specialized injectable dosage forms and Ophthalmic drops.

Founded

1990

HQ

Employees

990

Website

caplinpoint.net

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $230M

EBITDA: $80M

EV

$1B

Valuation Multiples

Multiples.vc

Start free trial

Caplin Point Laboratories Financials

Caplin Point Laboratories reported last 12-month revenue of $230M and EBITDA of $80M.

In the same LTM period, Caplin Point Laboratories generated $80M in EBITDA and $67M in net income.

Caplin Point Laboratories P&L

In the most recent fiscal year, Caplin Point Laboratories reported revenue of $223M and EBITDA of $80M.

Caplin Point Laboratories expects next 12-month revenue of XXX and NTM EBITDA of XXX

Caplin Point Laboratories Stock Performance

Caplin Point Laboratories has current market cap of $1B, and enterprise value of $1B.

Caplin Point Laboratories' stock price is $19.14.

Caplin Point Laboratories Valuation Multiples

Caplin Point Laboratories trades at 5.8x EV/Revenue multiple, and 16.7x EV/EBITDA.

Caplin Point Laboratories Financial Valuation Multiples

As of April 19, 2026, Caplin Point Laboratories has market cap of $1B and EV of $1B.

Equity research analysts estimate Caplin Point Laboratories' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Caplin Point Laboratories has a P/E ratio of 21.6x.

Caplin Point Laboratories Margins & Growth Rates

Caplin Point Laboratories' revenue in the last 12 month grew by 12%.

Caplin Point Laboratories' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Caplin Point Laboratories' rule of 40 is 46% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Caplin Point Laboratories' rule of X is 63% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Caplin Point Laboratories Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Caplin Point Laboratories M&A Activity

Caplin Point Laboratories acquired XXX companies to date.

Last acquisition by Caplin Point Laboratories was on XXXXXXXX, XXXXX. Caplin Point Laboratories acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Caplin Point Laboratories Investment Activity

Caplin Point Laboratories invested in XXX companies to date.

Caplin Point Laboratories made its latest investment on XXXXXXXX, XXXXX. Caplin Point Laboratories invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).